<VariationArchive VariationID="984695" VariationName="NM_003560.4(PLA2G6):c.319del (p.Leu107fs)" VariationType="Deletion" Accession="VCV000984695" Version="16" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-15" DateCreated="2020-11-14" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="972802" VariationID="984695">
      <GeneList>
        <Gene Symbol="PLA2G6" FullName="phospholipase A2 group VI" GeneID="8398" HGNC_ID="HGNC:9039" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38111495" stop="38181830" display_start="38111495" display_stop="38181830" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38507501" stop="38577835" display_start="38507501" display_stop="38577835" Strand="-" />
          </Location>
          <OMIM>603604</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_003560.4(PLA2G6):c.319del (p.Leu107fs)</Name>
      <CanonicalSPDI>NC_000022.11:38145543:GG:G</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38145544" stop="38145544" display_start="38145544" display_stop="38145544" variantLength="1" positionVCF="38145543" referenceAlleleVCF="AG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38541551" stop="38541551" display_start="38541551" display_stop="38541551" variantLength="1" positionVCF="38541550" referenceAlleleVCF="AG" alternateAlleleVCF="A" />
      </Location>
      <OtherNameList>
        <Name>NM_003560.4(PLA2G6):c.319del</Name>
        <Name>p.Leu107fs</Name>
      </OtherNameList>
      <ProteinChange>L107fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.38541552del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.38541552del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.38145545del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.38145545del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007094.2" sequenceAccession="NG_007094" sequenceVersion="2" change="g.65147del">
            <Expression>NG_007094.2:g.65147del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001004426.3" sequenceAccession="NM_001004426" sequenceVersion="3" change="c.319del">
            <Expression>NM_001004426.3:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001004426.1" sequenceAccession="NP_001004426" sequenceVersion="1" change="p.Leu107fs">
            <Expression>NP_001004426.1:p.Leu107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199562.3" sequenceAccession="NM_001199562" sequenceVersion="3" change="c.319del">
            <Expression>NM_001199562.3:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001186491.1" sequenceAccession="NP_001186491" sequenceVersion="1" change="p.Leu107fs">
            <Expression>NP_001186491.1:p.Leu107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349864.2" sequenceAccession="NM_001349864" sequenceVersion="2" change="c.319del">
            <Expression>NM_001349864.2:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336793.1" sequenceAccession="NP_001336793" sequenceVersion="1" change="p.Leu107fs">
            <Expression>NP_001336793.1:p.Leu107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349865.2" sequenceAccession="NM_001349865" sequenceVersion="2" change="c.319del">
            <Expression>NM_001349865.2:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336794.1" sequenceAccession="NP_001336794" sequenceVersion="1" change="p.Leu107fs">
            <Expression>NP_001336794.1:p.Leu107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349866.2" sequenceAccession="NM_001349866" sequenceVersion="2" change="c.319del">
            <Expression>NM_001349866.2:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336795.1" sequenceAccession="NP_001336795" sequenceVersion="1" change="p.Leu107fs">
            <Expression>NP_001336795.1:p.Leu107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349867.2" sequenceAccession="NM_001349867" sequenceVersion="2" change="c.-216del">
            <Expression>NM_001349867.2:c.-216del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349868.2" sequenceAccession="NM_001349868" sequenceVersion="2" change="c.-172del">
            <Expression>NM_001349868.2:c.-172del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349869.2" sequenceAccession="NM_001349869" sequenceVersion="2" change="c.-216del">
            <Expression>NM_001349869.2:c.-216del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003560.4" sequenceAccession="NM_003560" sequenceVersion="4" change="c.319del" MANESelect="true">
            <Expression>NM_003560.4:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003551.2" sequenceAccession="NP_003551" sequenceVersion="2" change="p.Leu107fs">
            <Expression>NP_003551.2:p.Leu107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015t1" sequenceAccession="LRG_1015t1">
            <Expression>LRG_1015t1:c.319del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1015p1" sequenceAccession="LRG_1015p1" change="p.Leu107fs">
            <Expression>LRG_1015p1:p.Leu107fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="776376695" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.319del (p.Leu107fs) AND Neurodegeneration with brain iron accumulation 2B" Accession="RCV001264800" Version="2">
        <ClassifiedConditionList TraitSetID="1719">
          <ClassifiedCondition DB="MedGen" ID="C1857747">Neurodegeneration with brain iron accumulation 2B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.319del (p.Leu107fs) AND PLA2G6-associated neurodegeneration" Accession="RCV002537674" Version="4">
        <ClassifiedConditionList TraitSetID="33682">
          <ClassifiedCondition DB="MedGen" ID="CN204472">PLA2G6-associated neurodegeneration</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.319del (p.Leu107fs) AND not provided" Accession="RCV002224044" Version="13">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-05-01" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-05-01" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2020-11-14" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16783378</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20619503</ID>
        </Citation>
        <DescriptionHistory Dated="2022-04-23">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33682" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18389" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">phospholipase A2-associated neurodegeneration</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">PLA2G6-associated neurodegeneration</ElementValue>
                <XRef ID="MONDO:0017998" DB="MONDO" />
                <XRef ID="329303" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PLAN</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12567" />
                <XRef ID="12567" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="329303" DB="Orphanet" />
              <XRef ID="CN204472" DB="MedGen" />
              <XRef ID="MONDO:0017998" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1719" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5629" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neurodegeneration with brain iron accumulation 2B</ElementValue>
                <XRef ID="MONDO:0012444" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEUROAXONAL DYSTROPHY, ATYPICAL</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, PLA2G6-RELATED</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">aNAD</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">atypical Neuroaxonal Dystrophy (aNAD)</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NBIA2B</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10688" />
                <XRef ID="10688" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C1857747" DB="MedGen" />
              <XRef ID="MONDO:0012444" DB="MONDO" />
              <XRef Type="MIM" ID="610217" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2850314" SubmissionDate="2020-10-08" DateLastUpdated="2020-11-14" DateCreated="2020-11-14">
        <ClinVarSubmissionID localKey="NM_001004426.1:c.319del|OMIM:610217" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001443044" DateUpdated="2020-11-14" DateCreated="2020-11-14" Type="SCV" Version="1" SubmitterName="Institute of Human Genetics, University of Leipzig Medical Center" OrgID="506086" OrganizationCategory="clinic" OrgAbbreviation="UKL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Review of the variants reported in Reuter et al., 2017, PMID: 28097321: PVS1,PM2,PM3_Supporting</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>biparental</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">profound ID</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">mental deterioration</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">muscular hypotonia</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">cerebellar atrophy</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">axonal degeneration</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001004426.1:c.319del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="610217" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8291144</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4893978" SubmissionDate="2022-04-22" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey=":Chr.22_38541550_AG_A|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002502134" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="AiLife Diagnostics, AiLife Diagnostics" OrgID="507594" OrganizationCategory="laboratory" OrgAbbreviation="AiLife" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16783378</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20619503</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">no</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="22" alternateAllele="A" referenceAllele="AG" start="38541550" stop="38541551" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11350707</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5052638" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2022-10-22">
        <ClinVarSubmissionID localKey="119786|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002585935" DateUpdated="2024-07-15" DateCreated="2022-10-22" Type="SCV" Version="12" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-05-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>PLA2G6: PVS1, PM2, PM3</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="22" alternateAllele="A" referenceAllele="AG" start="38541550" stop="38541551" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6450203" SubmissionDate="2023-01-27" DateLastUpdated="2023-02-07" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="35bddd84-871b-4a34-a850-6cbd67cae885" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003761025" DateUpdated="2023-02-07" DateCreated="2023-02-07" Type="SCV" Version="1" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Leu107fs variant in PLA2G6 has been reported in 1 individual, in the homozygous state, with PLA2G6-associated neurodegeneration (PMID: 28097321), and has been identified in 0.0009% (1/113112) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs776376695). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 984695) and has been interpreted as pathogenic by Institute of Human Genetics (University of Leipzig Medical Center). This variant is predicted to cause a frameshift, which alters the protein‚Äôs amino acid sequence beginning at position 107 and leads to a premature termination codon 4 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the PLA2G6 gene is an established disease mechanism in PLA2G6-associated neurodegeneration. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PVS1, PM2_supporting, PM3_supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_003560.4(PLA2G6):c.319del</Name>
            <Name>p.Leu107fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.11:g.38145545del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0017998" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12627697</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5052638" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2850314" TraitType="Finding" MappingType="Name" MappingValue="profound ID" MappingRef="Preferred">
        <MedGen CUI="None" Name="profound ID" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2850314" TraitType="Disease" MappingType="XRef" MappingValue="610217" MappingRef="OMIM">
        <MedGen CUI="C1857747" Name="Neurodegeneration with brain iron accumulation 2B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2850314" TraitType="Finding" MappingType="Name" MappingValue="axonal degeneration" MappingRef="Preferred">
        <MedGen CUI="C1837496" Name="Axonal degeneration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2850314" TraitType="Finding" MappingType="Name" MappingValue="cerebellar atrophy" MappingRef="Preferred">
        <MedGen CUI="C0740279" Name="Cerebellar atrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2850314" TraitType="Finding" MappingType="Name" MappingValue="muscular hypotonia" MappingRef="Preferred">
        <MedGen CUI="C0026827" Name="Hypotonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2850314" TraitType="Finding" MappingType="Name" MappingValue="mental deterioration" MappingRef="Preferred">
        <MedGen CUI="C0234985" Name="Mental deterioration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6450203" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0017998" MappingRef="MONDO">
        <MedGen CUI="CN204472" Name="PLA2G6-associated neurodegeneration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4893978" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

